CURRICULUM VITAE
`JEROLD CHUN
`
`Short Bio: Jerold Chun, MD, PhD, is Professor and Senior Vice
`President, Neuroscience Drug Discover at Sanford Burnham
`Prebys (SBP) Medical Discovery Institute in La Jolla, CA where he
`conducts basic and
`translational
`research, and oversees
`development of neuroscience programs having commercial and/or
`philanthropic potential. He is also Adjunct Professor in the
`Departments of Pharmacology and Neuroscience at the University
`of California at San Diego (UCSD) School of Medicine, and in the
`Department of Molecular and Cellular Neuroscience at The Scripps
`Research Institute (TSRI).
`
`He received his MD and PhD (Neuroscience) degrees through the
`Medical Scientist Training Program at Stanford University School of Medicine with Kavli Prize
`recipient Carla Shatz, moving east as a Helen Hay Whitney Postdoctoral Fellow at the Whitehead
`Institute for Biomedical Research–Massachusetts Institute of Technology where he worked with
`National Medal of Science recipient Dr. Rudolf Jaenisch and Nobel Laureate David Baltimore. He
`then joined the faculty at the UCSD School of Medicine, where he became Professor of
`Pharmacology and Neurosciences and directed the Neurosciences Graduate Program. He
`subsequently became Senior Director and Department Head of Molecular Neuroscience at Merck
`Research Laboratories, later returning to academia as Professor at TSRI, to arrive at his current
`position at SBP.
`
`He has made important contributions to our understanding of the brain and its diseases, including
`the discovery that our brains are composed of genomically distinct cells; that this genomic
`mosaicism offers a new mechanism for understanding the most common forms of Alzheimer’s
`disease and possibly other brain disorders; and in separate work, identified the first
`lysophospholipid receptor, which is a growing class of lipid receptors that has led to new
`neuroscience drugs (e.g., Gilenya for Multiple Sclerosis) and an understanding of other diseases
`including hydrocephalus, schizophrenia and fibrosis. Authoring more than 300 scientific papers,
`he has been recognized in Thomson Reuters’ World’s Most Influential Scientific Minds citation
`list, is a member of numerous editorial, advisory, and review boards; and has received many
`awards, including those from the NIH, Alfred P. Sloan Foundation, The Klingenstein Fund, and
`The March of Dimes.
`
`Dr. Chun has 22 years of continuous experience with the Biotechnology and Pharmaceutical
`industry. He participated in all major stages of the development of fingolimod (Gilenya, Novartis),
`from basic science, preclinical studies through post-marketing and commercial activities: Gilenya
`is the top product at Novartis, with over $3.1 billion (USD) in 2017. He sat on the scientific advisory
`board for Amira Pharmaceutical (Versant Ventures), which was sold to Bristol-Meyers-Squibb for
`~$475 million for a program based upon the receptor that he had discovered, LPA1.
`
`Contribution to Science
`
`
`the
`initiation of
`receptor and
`lysophospholipid
`first
`the
`1. Discovery of
`lysophospholipid receptor field. Lysophospholipids (LPs) are small, membrane-
`derived lipids that were thought to produce extracellular effects by different mechanisms
`– e.g., as detergents, calcium chelation, second messengers – with no receptors
`identified. Through studies of the embryonic brain, we discovered the first such receptor
`(Hecht, Weiner et al. 1996) for an LP known as lysophosphatidic acid (LPA), now known
`as LPA1, allowing subsequent de-orphanization of other LP receptors for LPA,
`sphingosine 1-phosphate (S1P), and other LPs. This class of lipid receptors now
`
`
`
`1
`
`Apotex v. Novartis
`IPR2017-00854
`NOVARTIS 2099
`
`

`

`constitutes around 40% of the known lipid G protein-coupled receptors, with thousands of
`papers published since our first report in 1996, and the entry of the human medicine
`fingolimod (Gilenya) for treating multiple sclerosis. We have been involved in many
`advances in this area including the first LPA receptor knockout (Contos, Fukushima et al.
`2000), receptor-mediated effects on the developing brain (Kingsbury, Rehen et al. 2003),
`and most recently, a crystal structure for LPA1 (Chrencik, Roth et al. 2015) that provided
`a first structural link between LP and endocannabinoid signaling.
`a. Chrencik JE, Roth CB, Terakado M, Kurata H, Oumi R, Kihara Y, Warshaviak D,
`Nakade S, Asmar-Rovira G, Mileni M, Mizuno H, Griffith MT, Rodgers C, Han GW,
`Velasquez J, Chun J*, Stevens RC*, Hanson MA*. Crystal structure of human
`lysophosphatidic acid receptor 1. Cell 2015;161:1633-1643. *co-senior authors.
`PMC4476059
`b. Contos JJA, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1
`lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci
`USA 2000;97:13384-13389. PMC27233
`c. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene -1 (Vzg-1) encodes a
`lysophosphatidic acid receptor expressed in neurogenic regions of the developing
`cerebral cortex. J Cell Biol 1996;135:1071-1083. PMC2133395
`d. Kingsbury MA, Rehen SK, Contos JJA, Higgins C, Chun J. Non-proliferative effects
`of lysophosphatidic acid enhance cortical growth and folding. Nature Neurosci
`2003;6:1292-1299.
`
`2. Discovery of somatically derived genomic mosaicism in the brain and its role in
`sporadic Alzheimer’s disease. Cells of the brain – as with almost all cells of the body –
`were historically thought to have identical and constant genomes. We identified
`recombination-activating gene 1 (RAG1) in the brain (Chun, Schatz et al. 1991),
`supporting the possibility of individually altered genomes in the brain, and stimulating a
`search for genomic diversity. We discovered the first evidence for this through
`aneuploidies (Rehen, McConnell et al. 2001) – gains and/or losses of chromosomes
`representing the first described somatic copy number variants (CNVs) in neural cells –
`which produce mosaicism and are part of the normal brain, with aneuploid neurons
`integrated into functional neural circuitry (Kingsbury, Friedman et al. 2005). Multiple other
`forms of somatic genomic mosaicism have subsequently been identified and we recently
`reported its operation in sporadic Alzheimer’s disease (Bushman, Kaeser et al. 2015)
`(accounting for ~99% of cases vs. familial disease), which may help to understand and
`treat AD, and serve as a model for other sporadic or idiopathic brain disorders. These
`studies have driven single-cell analyses to reveal an enormously diverse landscape of
`distinct genomic and transcriptomic signatures within and amongst individual brain cells.
`
`a. Bushman DM, Kaeser GE, Siddoway B, Westra JW, Rivera RR, Rehen SK, Yung YC,
`Chun J. Genomic mosaicism with increased amyloid precursor protein (APP) copy
`number in single neurons from sporadic Alzheimer’s disease brains. eLife
`2015;4:e05116. doi:10.7554/eLife.05116. PMC4337608
`b. Lake BB, Ai R, Kaeser GE, Salathia NS, Yung YC, Liu R, Wildberg A, Gao D, Fung H-
`L, Chen S, Vijayaraghavan R, Wong J, Chen C, Sheng X, Kaper F, Shen R, Ronaghi
`M, Fan J-B, *Wang W, *Chun J, *Zhang K. Neuronal subtypes and diversity revealed
` Science
`by single-nucleus RNA sequencing of
`the human brain.
`2016;352(6293):1586-1590. *Co-senior authors
`c. Chun JJM, Schatz DG, Oettinger MA, Jaenisch R, Baltimore D. The recombination
`activating gene-1 (RAG-1) transcript is present in the murine central nervous system.
`Cell 1991;64:189-200.
`d. Kingsbury MA, Friedman B, McConnell MJ, Rehen SK, Yang AH, Kaushal D, Chun J.
`Aneuploid neurons are functionally active and integrated into brain circuitry. Proc Natl
`Acad Sci USA 2005;102:6143-6147. PMC1087909
`
`2
`
`
`
`
`
`
`
`

`

`e. Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J.
`Chromosomal variation in neurons of the developing and adult mammalian nervous
`system. Proc Natl Acad Sci USA, 2001;98:13361-13366. PMC60876
`
`3. Discovery of major disease links involving disruption of lysophospholipid
`signaling. A major emphasis for our lab has been identifying lysophospholipid (LP)
`receptor roles in disease. A genuinely remarkable spectrum of pathogenic activities have
`emerged affecting multiple organ systems and we have driven studies identifying novel
`roles for LPA or S1P receptors in medically important areas that include: infertility (Ye,
`Hama et al. 2005), CNS mechanisms in multiple sclerosis (Choi, Gardell et al. 2011),
`hypoxic brain damage (Herr, Herr et al. 2011), and hydrocephalus (Yung, Mutoh et al.
`2011).
`a. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu
`M, Kennedy G, Chun J. FTY720 (fingolimod) efficacy in an animal model of multiple
`sclerosis requires astrocyte sphingosine 1-phosphate receptor (S1P1) modulation.
`Proc Natl Acad Sci USA 2011;108(2):751-756. PMC3021041
`b. Herr KJ, Herr DR, Lee CW, Noguchi K, Chun J. Stereotyped fetal brain disorganization
`is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling.
`Proc Natl Acad Sci USA 2011;108(37):15444-15449. PMC3174597
`c. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Arai
`H, Aoki J, Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo
`implantation and spacing. Nature 2005;435:104-108. PMC1369590
`d. Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, Kingsbury MA, Chun J.
`Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl Med
`2011;3:99ra87. PMC3653407
`
`4. Discovery of extensive programmed cell death in the embryonic brain. In the early
`1990s, programmed cell death – apoptosis – was assumed to be non-existent or trivial in
`the embryonic brain. We developed more sensitive detection techniques to show that
`death amongst neuroprogenitor cells was occurring (Blaschke, Staley et al. 1996,
`Blaschke, Weiner et al. 1998), which provided a mechanistic explanation for the
`phenotypes of caspase-null mice (that have grossly enlarged brains). The techniques
`stemming from these studies have been used in the field (Yung, Kennedy et al. 2009),
`and continue to reveal linkage to developmental mechanisms such as genomic mosaicism
`(Peterson, Yang et al. 2012).
`a. Blaschke AJ, Staley K, Chun J. Widespread programmed cell death in proliferative
`and postmitotic regions of the fetal cerebral cortex. Development 1996;122:1165-
`1174.
`b. Blaschke AJ, Weiner JA, Chun J. Programmed cell death is a universal feature of
`embryonic and postnatal neuroproliferative regions throughout the CNS. J Comp
`Neurol 1998;396:39-50.
`c. Peterson SE, Yang AH, Bushman DM, Westra JW, Yung YC, Barral S, Mutoh T,
`Rehen SK, Chun J. Aneuploid cells are differentially susceptible to caspase-mediated
` J Neurosci
`death during embryonic cerebral cortical development.
`2012;32(46):16213-16222. PMC361449
`d. Yung YC, Kennedy G, Chun J. Identification of neural programmed cell death through
`the detection of DNA fragmentation in situ and by PCR. In Current Protocols in
`Neuroscience, Unit 3.8, Taylor G (Ed.), John Wiley & Sons, July 2009. PMC2774705
`
`5. Defining subplate neurons in the developing cerebral cortex. The subplate is a
`developmentally transient structure that has importance in organizing the cerebral cortex.
`Anatomical studies in the 1980s suggested that some of the cells were neurons, however
`this was not proven. My PhD work defined them as peptidergic neurons (Chun, Nakamura
`
`3
`
`
`
`
`
`
`
`
`
`

`

`
`
`et al. 1987, Chun and Shatz 1989) representing both subplate and Cajal-Retzius cells that
`received synaptic connections (Chun and Shatz 1988), with a small sub-population
`surviving as what had been known as “interstitial neurons” (Chun and Shatz 1989).
`
`a. Chun JJM, Nakamura MJ, Shatz CJ. Transient cells of the developing mammalian
`telencephalon are peptide-immunoreactive neurons. Nature 1987;325:617-620.
`b. Chun JJM, Shatz CJ. Redistribution of synaptic vesicle antigens is correlated with the
`disappearance of a transient synaptic zone in the developing cerebral cortex. Neuron
`1988;1:297-310.
`c. Chun JJM, Shatz CJ. The earliest-generated neurons of the cat cerebral cortex:
`characterization by MAP2 and neurotransmitter immunohistochemistry during fetal life.
`J Neurosci 1989;9:1648-1667.
`d. Chun JJM, Shatz CJ. Interstitial cells of the adult neocortical white matter are the
`remnant of the early generated subplate neuron population. J Comp Neurol
`1989;282:555-569.
`
`
`Complete List of Published Work in my Bibliography
`http://www.ncbi.nlm.nih.gov/sites/myncbi/jerold.chun.1/bibliography/43724733/public/?sort=date&direction
`=ascending
`
`
`Contact Address
`Jerold Chun, MD, PhD
`Sanford Burnham Prebys Medical Discovery Institute
`10901 North Torrey Pines Road
`La Jolla, CA 92037
`Tel: 858-795-5024; Email jchun@sbpdiscovery.org
`http://sbpdiscovery.org/chunlab
`
`
`Citizenship USA
`
`Education
`Postdoctoral Fellow, Whitehead Institute for Biomedical Research/MIT
`1988-1991
`1981-1988 M.D.-Ph.D. (Neurosciences), Stanford University School of Medicine
`1977-1981
`B.A. (High Honors) in English and Biology, The University of Hawaii at Manoa
`
`Academic Research and Professional Experience
`2016-
`Professor and Senior Vice President of Neuroscience Drug Discovery, Sanford
`Burnham Prebys Medical Discovery Institute
`Adjunct Professor, Neuroscience Department, Investigator, Dorris Neuroscience
`Center, TSRI
`Professor, Molecular and Cellular Neuroscience Department, Investigator, Dorris
`Neuroscience Center, TSRI
`Professor, Department of Molecular Biology, The Scripps Research Institute,
`Investigator, Dorris Neuroscience Center
`Adjunct Professor of Neuroscience, UC San Diego (UCSD)
`Adjunct Professor of Pharmacology, UCSD
`Professor of Pharmacology, UCSD
`Acting Director, Neurosciences Graduate Program, UCSD
`Associate Director, Neurosciences Graduate Program, UCSD
`Associate Professor (with tenure), Department of Pharmacology, and Member,
`Neurosciences and Biomedical Sciences Programs
`Executive Committee Member, Neurosciences Graduate Program, UCSD
`Assistant Professor, Department of Pharmacology and Member, Neurosciences
`
`2003-
`2002-
`2001-2002
`2000-2001
`1999-2001
`1998-2001
`
`2016-
`
`2013-2016
`
`2003-2012
`
`1995-
`1991-1998
`
`
`4
`
`

`

`and Biomedical Sciences Programs, UCSD School of Medicine
`
`
`Postdoctoral Fellow, Whitehead Institute
`1988-1991
`1981-1988 M.D.-Ph.D. (MSTP) candidate, Department of Neurobiology, Stanford University
`
`
`School of Medicine
`1979-1981
`Undergraduate honors thesis student, Pacific Biomedical Research Center,
`
`
`University of Hawaii
`
`Academic Review and Advisory Positions
`2017
`Reviewer and Chair, NIA Alzheimer’s Disease in the Post Genomics Era RFA
`2017
`Reviewer, NIH Vascular Cell and Molecular Biology
`2015-
`Editorial Board Member, Scientific Reports (Nature)
`2013-
`Member, Next Generation and Science Educator Awards Selection Committee,
`Society for Neuroscience
`Reviewer, Scientific and Medical Review Committee, Hydrocephalus Association
`2012-
`Reviewer, Scripps Translational Science Institute Pilot Awards Program
`2012-
`Reviewer, Swiss MS Society
`2012
`Reviewer, MS Research Australia (MSRA)
`2012
`Reviewer, French Multiple Sclerosis Society (ARSEP)
`2012
`Reviewer, BSF (United States-Israel Binational Science Foundation)
`2012
`Reviewer, The Wellcome Trust
`2012-
`Chair, Hydrocephalus Association Review Panel
`2011
`Reviewer, Italian Multiple Sclerosis Society (FISM)
`2011
`Member, Board of Prostaglandins and Other Lipid Mediators
`2010
`Reviewer, NCI Discovery and Development Special Emphasis Panel P01
`2010
`2010-2012 Member, College of CSR Reviewers, NIH
`2010
`Reviewer, NIMH Sensitive Period RFA
`2010
`Reviewer, NCI, Discovery, Development, and Diagnosis P01
`2009-
`Editorial Board, Eye and Brain
`2009
`Reviewer, NIH ARRA Challenge Grants in Health and Science Research
`2009
`Reviewer, NIMH ARRA Autism RFA
`2008-
`Co-Chair, Novartis FTY Mechanism of Action Advisory Board
`2008
`Reviewer, Special Emphasis Panel, Support of Competitive Research (SCORE)
`Awards, NIGMS
`Reviewer, Cancer Research, UK
`Editorial Advisory Board, Current Pharmaceutical Design
`Editorial Board Member, Open Neuroscience (ON) Journal
`Associate Editor, “Prostaglandin and Lipid Mediators,” Bentham Science Pub
`Reviewer, Deutsche Forschungsgemeinschaft (DFG), Germany
`Reviewer, The Wellcome Trust, UK
`Byrd Alzheimer’s Reviewer
`Chairman, External Advisory Committee, RCMI/NINDS University of Hawaii
`Regular Member, NIH MBPP study section
`March of Dimes, Basil O’Connor Scholars Committee
`External Reviewer, Biotechnology and Biological Sciences Research Council
`(BBRC), UK
`External reviewer, The Netherlands Organisation for Health Research and
`Development
`External reviewer, Genome British Columbia
`Scientific Advisory Committee, Special Neuroscience Research Program
`(NINDS, University of Hawaii)
`External Reviewer, Sass Foundation
`Editorial Board Member, Journal of Biological Chemistry
`Permanent Member, MDCN-6, NIH
`Editorial Board, Journal of Molecular Medicine
`
`2004
`2000-2005
`2000-2003
`2001-
`
`
`
`5
`
`2008-
`2007-
`2007-
`2007-
`2006-
`2006-
`2006
`
`2006-
`2005-2008
`2004-
`2004-
`
`2004
`
`2004
`2004-
`
`

`

`2000-
`2000-
`
`External reviewer, Human Frontier Sciences Program
`External Advisory Committee, Research Centers in Minority Institutions (RCMI,
`NCRR/NIH supported), University of Hawaii
`External consultant, University of Hawaii School of Medicine
`Reviewer, Alzheimer’s Disease Association
`Ad hoc Member, MDCN-6, NIH
`NIMH Special Emphasis Panel
`Permanent Member, NIMH Molecular, Cellular and Developmental Neuroscience
`Ad Hoc Reviewer, NSF
`
`2011
`2010
`
`
`2007
`1999-2006
`1994-1999
`1993-1995
`1992-1995
`1992-1994
`1988-1991
`1981-1988
`
`1983
`
`2000-
`1998-
`1998-2000
`1999
`
`1996-1998
`1990-
`
`Ad Hoc Reviewer: Nature/Science/Nature Genetics/PNAS/Development/Neuron/Nature
`Neuroscience/ J. Neuroscience/ J. Cell Biology/Mol. Cell. Biol./ J. Comp. Neurol./European J.
`Neurosci./ Mol. Cell. Neurosci./ J. Neurobio./ J. Biol. Chem./Genomics/Oncogene/ Mol. Pharm./
`Exp. Neurol./Exp. Cell Sci./Glia/Develop. Dynam./J. Cell Science/FEBS
`Letters/TIPS/Neuroscience/J. Neurochem./J. Immunol./Biochim. Biophys. Acta./Analytical
`Biochem. Science/Natur Wissenschaft/Lipids/Life Sciences/Others
`
`Honors and Awards
`2016
`Alzheimer’s San Diego Researcher of the Year
`2014
`Thomson Reuters World’s Most Influential Scientific Minds list of highly cited
`researchers
`Killam Lecturer, Montreal Neurological Institute
`Journal of Lipid Research Lecturer, Keystone Symposium on Bioactive Lipids:
`Biochemistry and Diseases, Kyoto, Japan
`Chancellor’s Award for Excellence in Neuroscience, LSU Medical School
`Independent Scientist Award, NIMH
`First Award, NIMH
`Basil O'Connor Scholar (March of Dimes Birth Defects Foundation), UCSD
`Klingenstein Fellow in the Neurosciences, UCSD
`Alfred P. Sloan Research Fellow, UCSD
`Helen Hay Whitney Fellow, Whitehead Institute for Biomedical Research
`Trainee, Medical Scientist Training Program (MSTP), Stanford University School
`of Medicine
`Grass Fellowship, Cold Spring Harbor Laboratory course in Molecular and
`Cellular Neurobiology
`Dean prize, outstanding senior thesis in the natural sciences, Univ. Hawaii
`B.A. with high honors in English and Biology, University of Hawaii, Manoa
`
`
`
`
`1981
`1981
`
`Industrial/Business Experience (Consultant, advisor and/or research collaborator)
`2018
`Scientific Advisory Board, Aardvark Therapeutics
`2018-
`Chair, Scientific Advisory Board, Brainstorm Cell Therapeutics
`2017
`BioLineRx
`2015-
`Inception Sciences
`2013-2014
`RuiYi
`2012-
`Johnson & Johnson
`2012-
`Arena Pharmaceuticals
`2011-2017
`Abbott/Abbvie
`2011-
`Celgene
`2010-2012 GSK
`2010-
`Ono Pharmaceutical Co., Ltd.
`2010-2015
`Biogen Idec
`2010-
`Novartis Pharmaceuticals Corporation
`2009-2017 Member, co-Chair, Chair Fingolimod/Gilenya advisory boards, Novartis
`2008-2011
`Scientific Advisory Board, Amira Pharmaceuticals
`
`
`
`6
`
`

`

`2010-2013 Mitsubishi Tanabe
`2007-2010
`Pfizer
`2009-2012
`Taisho Pharmaceutical Co., Ltd.
`2005-
`Scientific Advisory Board, Cellular Bioengineering, Inc./SKAI ventures
`2005-2007
`Scientific Advisor, CMX Capital
`2003-2005
`Scientific Advisor, Novel Bioventures
`2002-
`Novartis Pharma AG
`2001-2005
`University Inventions
`2000-2003 Merck & Co., Inc. (consultant, Senior Director, founding Department Head,
`Molecular Neuroscience, Merck Research Labs, San Diego, CA)
`Allelix Biopharmaceuticals/NPS Pharmaceuticals
`
`
`
`2013
`2013
`
`2013
`2014
`2014
`
`2014
`
`2014
`
`2014
`
`1996-2000
`
`Invited Talks (last 5 years)
`2013
`Vanderbilt Institute of Chemical Biology, Nashville, TN
`2013
`Frontiers in Biomedical Research Symposium, Indian Wells, CA
`2013
`California Multiple Sclerosis Research Forum 2013, Redondo Beach, CA
`2013
`Seattle Children’s Research Institute, Seattle, WA
`2013
`ASBMB Annual Meeting, Boston, MA
`2013
`New York Academy of Sciences, Translating Natural Products into Drugs for
`Alzheimer’s and Neurodegenerative Disease, New York, NY
`FASEB meeting on Lysophospholipids, Sapporo,
`108th International Titisee Conference, “Causes and Consequences of
`Aneuploidy,” Titisee, Black Forest, Germany
`Siponimod Advisory Board, Zurich
`EpiCenter Symposium, “Innovation & Promise in Epilepsy Research,” Irvine, CA
`Biomarkers in Hydrocephalus, sponsored by the Hydrocephalus Association, St.
`Louis, MO
`Novartis Fingolimod Effects in Focal and Diffuse CNS Injury Advisory Board,
`Philadelphia, PA
`San Diego County Aging Summit, “Alzheimer’s on Trial: The Search for a Cure,”
`San Diego, CA
`NIH-NINDS Midbrain/Hindbrain Malformations and Hydrocephalus Workshop,
`Bethesda, MD
`2nd Lysophospholipid Signaling Conference of China, Beijing
`Novartis Progressive MS – Future Directions Advisory Board, Amsterdam,
`Netherlands
`6th International Conference on Phospholipase A2 and Lipid Mediators, Tokyo
`Novartis STEP PPMS Advisory Board Meeting, London
`Novartis Safety Barriers and Benefit-Risk Advisory Board, Jersey City, NJ
`Gachon University, Seongnam, Kyunggi-do, Korea
`Konkuk University, Seoul, Korea
`The IUPHAR World Conference on the Pharmacology of Natural and Traditional
`Medicine 2015, Singapore
`FASEB Lysophospholipid Meeting, Banff, Canada
`Korean Society for Molecular and Cellular Biology Society, Seoul, Korea
`Hydrocephalus Association Vision Dinner, Keynote Speaker, New York City, NY
`Novartis Monoclonal Antibodies and the Future of Multiple Sclerosis Advisory
`Board, Coral Gables, FL
`“Lysophospholipid receptors: from novel structures to CNS diseases,” 
`Universidade Federal do Rio de Janeiro; Fiocruz Institute; Institute D’Or; Brazil
`LIPID MAPS Annual Meeting, La Jolla, CA
`Lipid Mediators in Health and Disease II: From the Cutting Edge – A Tribute to
`Edward Dennis, 7th International Conference on Phospholipase A2 and Lipid
`Mediators: From Bench to Translational Medicine, La Jolla, CA
`
`2014
`2014
`
`2015
`2015
`2015
`2015
`2015
`2015
`
`2015
`2015
`2015
`2015
`
`2016
`
`2016
`2016
`
`
`
`7
`
`

`

`2016
`2016
`
`2016
`2016
`2016
`2016
`2016
`2017
`2017
`2017
`
`CSHL Single Cell Analysis, Cold Spring Harbor, NY
`FASEB SRC: Phospholipase Signaling in Cancer, Neurodegeneration and
`Cardiovascular Disease, Steamboat Springs, CO
`Universidad de Chile, Santiago, Chile
`University College London Institute of Neurology, Queen Square, London
`Babraham Institute, Cambridge
`Cambridge University, Cambridge
`National University of Singapore, Singapore
`Sixth Genome Dynamics in the Nervous System – GDN6, Hong Kong
`National University of Singapore, Singapore
`FASEB SRC: Lysophospholipid and Related Mediators: From Bench to Clinic,
`New Orleans, LA
`Max Planck Lecture, University of Tokyo, Japan
`Pasteur Institute, Paris, France
`UCSD, Alzheimer’s Disease Research Center Lecture Series
`UCSD, Department of Pathology Research Lecture Series
`SBP Sunrise Science Lecture Series
`
`2017
`2017
`2017
`2018
`2018
`
`Memberships
`1982-
`
`1998-
`
`2017-
`
`
`Patents
`U.S. Patent No.:
`Date:
`Title:
`Inventors:
`Application No.:
`Filed:
`
`6,140,060
`U.S. Patent No.:
`October 31, 2000
`Date:
`Jerold Chun et al.
`Applicant:
`US Application S.N.: 08/763,938; S/N 09/153,464
`Filed:
`December 12, 1996
`Title:
`Cloned Lysophosphatidic Acid Receptors
`
`U.S. Patent No.:
`Date:
`Applicant:
`Serial No.:
`Filed:
`Title:
`
`
`PUBLICATIONS (H-Index: 97)
`Articles/Letters
`1. Chun JJM, Nakamura MJ, Shatz CJ. Transient cells of the developing mammalian
`telencephalon are peptide-immunoreactive neurons. Nature 1987;325:617-620.
`
`2. Chun JJM, Shatz CJ. A fibronectin-like molecule is present in the developing cat cerebral
`cortex and is correlated with subplate neurons. J Cell Biol 1988;106:857-872.
`
`
`Society for Neuroscience
`Federation of American Societies for Experimental Biology
`American Neurological Association
`
`6,057,126
`May 2, 2000
`Mammalian EDG-5 Receptor Homologs
`Munroe, Donald; Gupta, Ashwani; Vyas, Tejal; Chun, Jerold
`997,803
`December 24, 1997
`
`6,150,345
`November 21, 2000
`Jerold J.M. Chun et al. Examiner: Michael Borin
`09/153,464Group Art Unit: 1654
`September 15, 1998 Docket: 1133.006US1
`Method for Promoting Survival of Myelin Producing Cells
`
`
`
`8
`
`

`

`3. Chun JJM, Shatz CJ. Redistribution of synaptic vesicle antigens is correlated with the
`disappearance of a transient synaptic zone in the developing cerebral cortex. Neuron
`1988;1:297-310.
`
`4. Chun JJM, Shatz CJ. Interstitial cells of the adult neocortical white matter are the remnant
`of the early generated subplate neuron population. J Comp Neurol 1989;282:555-569.
`
`5. Chun JJM, Shatz CJ. The earliest-generated neurons of the cat cerebral cortex:
`characterization by MAP2 and neurotransmitter immunohistochemistry during fetal life. J
`Neurosci 1989;9:1648-1667.
`
`6. Chun JJM, Schatz DG, Oettinger MA, Jaenisch R, Baltimore D. The recombination
`activating gene-1 (RAG-1) transcript is present in the murine central nervous system. Cell
`1991;64:189-200.
`
`Turka LA, Schatz DG, Oettinger MA, Chun JJM, Gorka C, Lee K, McCormack WT,
`7.
`Thompson CB. Thymocyte expression of the recombination activating genes RAG-1 and RAG-
`2 can be terminated by T-cell receptor stimulation in vitro. Science 1991;253:778-781.
`
`8. Chun JJM. A protocol using retrovirally-introduced multiple oncogenes in the production of
`neuron-like cell lines from the murine central nervous system. NeuroProtocols 1993;3:214-221.
`
`Blaschke AJ, Staley K, Chun J. Widespread programmed cell death in proliferative and
`9.
`postmitotic regions of the fetal cerebral cortex. Development 1996;122:1165-1174 (see
`comment in Neuron 1996;16:693).
`
`10. Chun J, Jaenisch R. Clonal cell lines produced by birth-date targeting of neocortical
`neuroblasts using multiple oncogenes transduced by retroviruses. Mol Cell Neurosci
`1996;7:304-321.
`
`11. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene -1 (Vzg-1) encodes a
`lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral
`cortex. J Cell Biol 1996;135:1071-1083.
`
`12. Staley K, Blaschke AJ, Chun J. Apoptotic DNA fragmentation is detected by a semi-
`quantitative ligation-mediated PCR of blunt DNA ends. Cell Death and Differen 1997;4:66-75.
`
`13. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. Identification of a novel protein kinase
`A anchoring protein that binds both type I and type II regulatory subunits. J Biol Chem
`1997;272:8057-8064.
`
`14. Weiner JA, Chun J. Png-1, a nervous system-specific zinc finger gene, identifies regions
`containing postmitotic neurons during mammalian embryonic development. J Comp Neurol
`1997;381:130-142.
`
`15. Weiner JA, Chun J. Maternally-derived immunoglobulin light chain is present in the fetal
`mammalian CNS. J Neurosci 1997;17:3148-3156.
`
`16. Bain G, Engel I, Maandag ECR, te Riele HPJ, Voland JR, Sharp LL, Chun J, Huey B,
`Pinkel D, Murre C. E2A deficient mice rapidly develop T cell leukemias. Mol Cell Biol
`1997;17:4782-4791.
`
`17. McWhirter JR, Goulding M, Weiner J, Chun J, Murre C. A novel fibroblast growth factor
`gene expressed in the developing nervous system is a downstream target of the chimeric
`
`
`
`9
`
`

`

`homeodomain oncoprotein E2A-Pbx1. Development 1997;124:3221-3232.
`
`18. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. D-AKAP2, a novel protein kinase A
`anchoring protein that contains a potential RGS domain. PNAS 1997;94:11184-11189.
`
`19. Blaschke AJ, Weiner JA, Chun J. Programmed cell death is a universal feature of
`embryonic and postnatal neuroproliferative regions throughout the CNS. J Comp Neurol
`1998;396:39-50.
`
`20. Fukushima N, Kimura Y, Chun J. A single receptor encoded by vzg-1/lpa1/edg-2 couples
`to G-proteins and mediates multiple cellular responses to lysophosphatidic acid (LPA). Proc
`Natl Acad Sci USA 1998;95:6151-6156.
`
`21. Pompeiano M, Hvala M, Chun J. Onset of apoptotic DNA fragmentation can precede cell
`elimination by days in the small intestinal vilus. Cell Death and Diff 1998;5:702-709.
`
`22. Weiner JA, Hecht JH, Chun J. The lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2
`is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J
`Comp Neurol 1998;398:587-589.
`
`23. Contos JJA, Chun J. Complete cDNA sequence, genomic structure and chromosomal
`localization of the LPA receptor gene, vzg-1/lpA1/Gpcr26. Genomics 1998;51:364-378.
`
`24. Zhang G, Contos JJA, Weiner JA, Fukushima N, Chun J. Comparative analysis of three
`murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 1999;227:89-
`99.
`
`25. Nagai Y, Onodera O, Chun J, Strittmatter WJ, Burke JR. Expanded polyglutamine domain
`proteins bind neurofilament and alter the neurofilament network. Exp Neurol 1999;155:195-
`203.
`
`26. Dubin AE, Bahnson T, Weiner JA, Fukushima N, Chun J. Lysophosphatidic acid (LPA)
`stimulates neurotransmitter-like conductance changes that precede GABA and L-glutamate in
`early, presumptive cortical neuroblasts. J Neurosci 1999;19:1371-1381.
`
`27. Weiner JA, Chun J. Schwann cell survival mediated by the signaling phospholipid
`lysophosphatidic acid. Proc Natl Acad Sci 1999;96:5233-5238.
`
`28. Marszalek JR, Weiner JA, Farlow SJ, Chun J, Goldstein LSB. Novel dendritic kinesin
`sorting identified by different process targeting of two related kinesins: KIF21A and KIF21B. J
`Cell Biol 1999;145:469-479.
`
`29. Gu Y, Sekiguchi J, Gao Y, Dikkes P, Frank K, Ferguson D, Hasty P, Chun J, Alt FW.
`Defective embryoic neurogenesis in ku, but not DNA-PKcs, deficient mice. Proc Natl Acad Sci
`USA 2000;97:2668-2673.
`
`30. Contos JJA, Chun J. Genomic characterization of the lysophosphatidic acid receptor
`gene, lpA2/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.
`Genomics 2000;64:155-169.
`
`31. Pompeiano M, Blaschke AJ, Flavell RA, Srinivasan A, Chun J. Decreased apoptosis in
`proliferative and postmitotic regions of the caspase 3 deficient embryonic CNS. J Comp
`Neurol 2000;423:1-12.
`
`
`
`
`10
`
`

`

`Ishii I, Contos JJA, Fukushima N, Chun J. Functional comparisons of the lysophosphatidic
`32.
`acid receptors LPA1, LPA2 and LPA3 in neuronal cell lines using a retrovirus expression system.
`Mol Pharmacol 2000;58:895-902.
`
`33. Fukushima N, Weiner JA, Chun J. Lysophosphatidic acid (LPA) is a novel extracellular
`regulator of cortical neuroblast morphology. Dev Biol 2000;228:6-18.
`
`34. Contos JJA, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1
`lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA
`2000;97:13384-13389.
`
`35. Contos JJA, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol
`2000;58:1188-1196.
`
`36. Hagihara K, Watanabe K, Chun J, Yu Yamaguchi Y. Glypican-4 is an FGF2-binding
`heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 2000;219:353-367.
`
`37. Kimura Y, Schmitt A, Fukushima N, Ishii I, Kimura H, Nebreda AR, Chun J. Two novel
`Xenopus homologs of mammalian LPA1/edg-2 function as lysophosphatidic acid receptors in
`Xenopus oocytes and mammalian cells. J Biol Chem 2001;276:15028-15215.
`
`38. Contos JJA, Chun J. The mouse lpA3/Edg7 lysophosphatidic acid receptor gene:
`sequence, genomic structure, chromosomal location and expression pattern. Gene
`2001;267:243-253.
`
`39. Moeller T, Contos JJ, Musante DB, Chun J, Ransom BR. Expression and function of
`lysophosphatidic acid receptors in cultured rodent micr